Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

Immunological Reviews

Volumn 170, Issue , 1999, Pages 29-38

  Schneider, Jörg ^a,c   Gilbert, Sarah C ^a   Hannan, Carolyn M ^a   Dégano, Pilar ^a   Prieur, Eric ^a   Sheu, Eric G ^a   Plebanski, Magdalena ^b   Hill, Adrian V S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b AUSTIN RESEARCH INSTITUTE   (Australia)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; MALARIA VACCINE;

IMMUNIZATION; MALARIA; PARASITE IMMUNITY; POXVIRUS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; MALARIA; MALARIA VACCINES; MICE; PRIMATES; VACCINES, DNA;

EID: 0032861392     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01326.x     Document Type: Review

References (63)

1. 1. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-358.
2. 2. Griffiths GM. Protein sorting and secretion during CTL killing. Semin Immunol 1997;9:109-115.
3. 3. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, and Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
4. + T cells. Science 1995;270:1811-1815.
5. + cell, interferon-γ, and nitric oxide-dependent immunity. J Exp Med 1996;183:1739-1746.
6. 6. Brunner KT, Mauel J, Cerottini JC, Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968;14:181-196.
7. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-142.
8. 8. Murali Krishna K, et al. Counting antigen-specific CD8 T cells: a re-evaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
9. 9. Altman JD, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96.
10. 10. Yewdell JW, Bennink JR. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 1992;52:1-123
11. 11. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity 1996;5:295-302.
12. 12. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-16.
13. 13. Fu TM, et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997;3:362-371.
14. 14. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
15. 15. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T tells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989;341:323-326.
16. 16. Hill AV, et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 1992;360:434-439.
17. 17. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967;216:160-162.
18. 18. Herrington D, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991;45:539-547.
19. 19. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
20. 20. Hartikka J, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996;7:1205-1217.
21. 21. Sato Y, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-354.
22. 22. Tobery T, Siliciano RF. Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 1999;162:639-642.
23. 23. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997;71:8497-8503.
24. 24. Kim JJ, et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998;28:1089-1103.
25. 25. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-1415.
26. 26. Fu TM, Guan L, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine 1998;16:1711-1717.
27. 27. Fuller DH, Corb MM, Barnett S, Steimer K, Haynes JR. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997;15:924-926.
28. 28. Wang R, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
29. 29. Donnelly JJ, et al. Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin. Proc Natl Acad Sci USA 1993;90:3530-3534.
30. + cytotoxic T cells. Vaccine 1994;12:73-80.
31. 31. Ke Y, Li Y, Kapp JA. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol 1995;25:549-553.
32. 32. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997;27:2340-2344.
33. 33. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989;342:561-564.
34. 34. Livingston BD, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997;159:1383-1392.
35. 35. Gilbert SC, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997;15:1280-1284.
36. 36. Speidel K, et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997;27:2391-2399.
37. 37. Klavinskis LS, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996;157:2521-2527.
38. 38. Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine 1995;13:1143-1151.
39. 39. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-11353.
40. 40. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
41. 41. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 1994;82:125-129.
42. 42. Kaplan C. Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch Virol 1989;106:127-139.
43. 43. Johnson DC, Hill AB. Herpesvirus evasion of the immune system. Curr Top Microbiol Immunol 1998;232:149-177.
44. 44. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-154.
45. 45. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst 1998;90:1881-1887.
46. 46. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994;68:8125-8130.
47. 47. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralbl Bakteriol B 1978;167:375-390.
48. 48. Antoine G, Scheiflinger GF, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998;244:365-396.
49. 49. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-1167.
50. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
51. 51. Plebanski M, et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998;28:4345-4355.
52. + T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine (In press).
53. 53. Allsopp CE, et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996;26:1951-1959.
54. 54. Sedegah M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998;95:7648-7653.
55. + T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 1994;153:4636-4648.
56. + T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996;173:96-107.
57. 57. Hanke T, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
58. 58. Hanke T, et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532.
59. 59. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw TA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72:10180-10188.
60. 60. Robinson HL, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunisations. Nat Med 1999;5:526-534
61. 61. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997;89:1595-1601.
62. + T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 1993;90:5214-5218.
63. 63. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996;272:1947-1950.